National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

plevitrexed
An orally bioavailable, small molecule, non-polyglutamatable, antifolate quinazoline derivative thymidine synthetase inhibitor with potential antineoplastic activity. Plevitrexed is transported into the cell via the physiological reduced folate carrier (RFC) system. Intracellularly, this agent selectively binds to the folate binding site of thymidylate synthase and inhibits thymidine synthesis, which may result in DNA synthesis inhibition and apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code names:BGC 9331
ZD9331
Chemical structure name:(2S)-2-[[4-[[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methy](prop-2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1H-tetrazol-5-yl)butanoic acid



Previous:Plan B, plant-derived hematopoiesis enhancer PG2, Platinol, Platinol-AQ, plerixafor
Next:plicamycin, plitidepsin, pneumococcal polyvalent vaccine, Pneumovax 23, pNGVL3-hICD vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov